# NRx Pharmaceuticals (NRXP) — Earnings

NRXP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nrxp/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q4 2025 |
| Period end | Dec 31, 2025 |
| EPS actual | $0.01 |
| EPS estimate | −$0.07 |
| EPS surprise | +114.29% |
| Revenue surprise | −72.83% |
| Revenue | $991,500.00 |
| Revenue estimate | $3.6M |
| Reported | Mar 23, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1719406/000143774926009418/nrxp20251231_10k.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/59a02e36-526a-c6b8-f210-ee09177ed890.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q4 2025 | Mar 23, 2026 | −$0.07 | $0.01 | 114.29% | $3.6M | $991,500.00 |
| Q3 2025 | Nov 14, 2025 | −$0.13 | −$0.27 | -105.79% | $6.0M | $242,000.00 |
| Q2 2025 | Aug 18, 2025 | −$0.15 | −$0.98 | -552.46% | $3.5M | — |
| Q1 2025 | May 15, 2025 | −$0.28 | −$0.34 | -20.01% | — | $2.3M |
| Q4 2024 | Mar 14, 2025 | −$0.37 | −$0.72 | -97.52% | — | — |
| Q3 2024 | Nov 14, 2024 | −$0.56 | −$0.15 | 72.97% | — | — |
| Q2 2024 | Aug 14, 2024 | −$0.70 | −$0.75 | -7.91% | — | — |
| Q1 2024 | May 14, 2024 | −$0.55 | −$0.74 | -34.55% | — | — |
| Q4 2023 | Mar 29, 2024 | −$0.70 | −$0.50 | 28.57% | — | — |
| Q3 2023 | Nov 14, 2023 | −$1.10 | −$0.70 | 36.36% | — | — |
| Q2 2023 | Aug 14, 2023 | −$1.33 | −$1.20 | 10.00% | — | — |
| Q1 2023 | May 15, 2023 | −$1.35 | −$1.60 | -18.52% | — | — |
| Q4 2022 | Mar 31, 2023 | −$1.45 | −$1.50 | -3.45% | — | — |
| Q3 2022 | Nov 14, 2022 | −$1.40 | −$1.40 | 0.00% | — | — |
| Q2 2022 | Aug 15, 2022 | −$1.00 | −$1.10 | -10.00% | — | — |
| Q1 2022 | May 16, 2022 | $0.00 | −$2.10 | 0.00% | — | — |

## Frequently Asked Questions

### When did NRx Pharmaceuticals (NRXP) last report earnings?

NRx Pharmaceuticals last reported on Mar 23, 2026, covering fiscal Q4 2025.

### Did NRXP beat earnings estimates?

Yes. NRx Pharmaceuticals reported EPS of $0.01 for Q4 2025 against a −$0.07 estimate — a 114.29% beat.

### How much revenue did NRXP report last quarter?

NRx Pharmaceuticals reported $991,500.00 in revenue for Q4 2025, against a consensus estimate of $3.6M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).